bristol_myers_squibb (biotechcompany)

literal strings:
  Bristol-Myers Squibb, Bristol Myers Squibb, Bristol-Myers-Squibb, bristol myers squibb, Bristol-myers Squibb, Bristol-myers squibb, BRISTOL MYERS SQUIBB, BRISTOL-MYERS SQUIBB, Bristol Myers-Squibb
  bristol myers squibb company, Bristol-Myers Squibb Company, Bristol Myers-Squibb Company, Bristol Myers Squibb Company
  bristol myers squibb co, BRISTOL MYERS SQUIBB CO, Bristol Myers Squibb Co, Bristol-Myers Squibb Co

Help NELL Learn!

NELL wants to know if these beliefs are correct.
If they are or ever were, click thumbs-up. Otherwise, click thumbs-down.

• bristol_myers_squibb is a biotech company     
• bristol_myers_squibb is a company     
• buspirone is a drug worked on by bristol_myers_squibb (biotechcompany)     
• carboplatin is a drug worked on by bristol_myers_squibb (biotechcompany)     
• didanosine is a drug worked on by bristol_myers_squibb (biotechcompany)     
• fosinopril is a drug worked on by bristol_myers_squibb (biotechcompany)     

categories

• biotechcompany(100.0%)
• OE @883 (90.5%) on 30-oct-2014 [ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://en.wikipedia.org/wiki/Bristol-Myers_Squibb http://www.bloomberg.com/quote/BMY:US http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://news.bms.com/press-release/bristol-myers-squibb-receives-us-fda-breakthrough-therapy-designation-all-oral-daclata http://www.linkedin.com/company/bristol-myers-squibb http://en.wikipedia.org/wiki/Bristol-Myers_Squibb http://en.wikipedia.org/wiki/Bristol-Myers_Squibb http://www.bmspaf.org/ http://www.reuters.com/finance/stocks/overview?symbol=BMY.N http://www.reuters.com/finance/stocks/overview?symbol=BMY.N http://news.bms.com/press-release/bristol-myers-squibb-receives-us-fda-breakthrough-therapy-designation-all-oral-daclata http://www.reuters.com/finance/stocks/overview?symbol=BMY.N http://en.wikipedia.org/wiki/Bristol-Myers_Squibb http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://www.bmscanada.ca/ http://www.bmspaf.or  ] using bristol_myers_squibb
• CPL @1103 (72.1%) on 08-mar-2018 [ "_ is a global pharmaceutical" "_ is a global pharmaceutical company" ] using bristol_myers_squibb
• OE @940 (100.0%) on 20-jul-2015 [ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/  ] using bristol_myers_squibb_company
• CMC @1066 (100.0%) on 12-jul-2017 [ LASTPREFIX=co 2.09587 WORDSHAPE=Aaaaaaa 1.66118 SHORT_WORDSHAPE=Aa 1.36720 SUFFIX=mpany 1.25221 SUFFIX=pany 1.25221 LASTSUFFIX=mpany 1.21034 LASTSUFFIX=pany 1.21034 CHARS -2.40624 SHORT_WORDSHAPE=a -2.76392 WORDS -4.05766 ] using bristol_myers_squibb_company
• CMC @1103 (100.0%) on 08-mar-2018 [ LAST_WORD=co 13.19720 CHARS 2.04653 PREFIX=br 1.01964 SUFFIX=bb 0.87904 WORDSHAPE=AA 0.61830 WORDSHAPE=Aa 0.61581 WORDSHAPE=Aaaaaaa 0.58277 POS=NNS -0.89895 SUFFIX=ol -1.61315 WORDS -4.54329 ] using bristol_myers_squibb_co
• CMC @1104 (100.0%) on 18-mar-2018 [ CHARS 5.69139 SUFFIX=bb 2.39250 PREFIX=br 1.67685 SUFFIX=ers 1.37114 WORDSHAPE=Aaaaaaa 1.34161 PREFIX=myer 1.30319 PREFIX=brist 1.24224 SHORT_WORDSHAPE=a -1.85004 SUFFIX=ol -3.02702 WORDS -10.95634 ] using bristol_myers_squibb
• CPL @1109 (62.0%) on 12-jun-2018 [ "medical affairs for _" "pharmaceutical sales representative for _" "development alliance with _" "educational grants from _" "_ is a global biopharmaceutical company" "assistance program provided by _" "drug manufactured by _" "_ is a global pharmaceutical" "educational grant provided by _" "research support from _" "speakersbureau for _" "discovery collaborations with _" "honoraria from _" "unofficial affiliation with _" "unrestricted research grants from _" "pharmaceutical companies such as _" "successful DD-year career at _" "collaboration agreement with _" "speakers bureau for _" "sponsoring companies include _" "business unit of _" "grant/research support from _" "drug discovery alliance with _" "unrestricted educational grants from _" "independent educational grant from _" "patient assistance program provided by _" "top sponsoring companies include _" "_ 's Pravachol" "news developments at _" "It is manufactured by _" "indirect wholly-owned subsidiary of _" "grant support from _" "educational grants provided by _" "drug discovery at _" "Technologies group at _" "independent educational grants from _" "unrestricted educational grant from _" "_ There are currently no resolutions" "recent news developments at _" "_ is a research-based pharmaceutical company" "educational grant from _" "biotechnology companies , including _" "medication is made by _" "major corporations such as _" "discovery alliance with _" "company acquired by _" "second-largest player was _" "medication made by _" "grants/research support from _" "drug made by _" "study was sponsored by _" "_ distributes this drug" ] using bristol_myers_squibb_company
• SEAL @209 (99.6%) on 14-feb-2011 [ 1 2 3 4 5 6 7 8 ] using bristol_myers_squibb
• SEAL @304 (100.0%) on 18-jun-2011 [ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 ] using bristol_myers_squibb_co
• OE @803 (94.4%) on 13-jan-2014 [   ] using bristol_myers_squibb_co
• SEAL @202 (54.9%) on 09-feb-2011 [ 1 2 ] using bristol_myers_squibb_company
• company(100.0%)
• SEAL @767 (58.9%) on 04-sep-2013 [ 1 ] using bristol_myers_squibb_company
• CMC @1108 (100.0%) on 06-jun-2018 [ SUFFIX=bb 9.11854 LASTSUFFIX=bb 6.17646 PREFIX=bri 2.27007 PREFIX=myer 1.84777 SHORT_WORDSHAPE=Aa 1.58800 PREFIX=squi 1.36471 PREFIX=mye 1.23881 CHARS -1.71315 WORDS -2.30489 SUFFIX=ol -5.51490 ] using bristol_myers_squibb
• OE @970 (100.0%) on 09-jan-2016 [ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/  ] using bristol_myers_squibb_co
• SEAL @43 (84.2%) on 02-feb-2010 [ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 ] using bristol_myers_squibb
• OE @949 (100.0%) on 20-sep-2015 [ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/ http://topics.nytimes.com/top/news/business/companies/bristol_myers_squibb_company/  ] using bristol_myers_squibb_company
• SEAL @671 (55.9%) on 17-dec-2012 [ 1 2 3 4 ] using bristol_myers_squibb_co
• CMC @901 (99.9%) on 13-feb-2015 [ SHORT_WORDSHAPE=Aa 3.18572 PREFIX=compa 2.16810 LASTSUFFIX=mpany 1.61606 LASTSUFFIX=pany 1.61606 LAST_WORD=company 1.61001 LASTPREFIX=compa 1.48029 SUFFIX=mpany 1.42230 SUFFIX=ol -2.10285 WORDS -2.61283 CHARS -4.24270 ] using bristol_myers_squibb_company
• CMC @1108 (100.0%) on 06-jun-2018 [ LAST_WORD=co 9.75630 SUFFIX=bb 4.05268 PREFIX=bri 1.00892 SHORT_WORDSHAPE=Aa 0.84693 PREFIX=myer 0.82123 POS=NN 0.68259 SHORT_WORDSHAPE=A 0.63154 CHARS -0.87561 WORDS -1.36586 SUFFIX=ol -2.45107 ] using bristol_myers_squibb_co

NELL has only weak evidence for items listed in grey

• retailstore
• SEAL @739 (72.4%) on 06-jun-2013 [ 1 2 ] using bristol_myers_squibb
• SEAL @785 (55.5%) on 02-nov-2013 [ 1 ] using bristol_myers_squibb_company

relations

• agentworkedondrug
• buspirone (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (buspirone, bristol_myers_squibb)
• OE @808 (100.0%) on 29-jan-2014 [   ] using (buspirone, bristol_myers_squibb)
• carboplatin (100.0%)
• OE @820 (92.4%) on 06-mar-2014 [   ] using (carboplatin, bristol_myers_squibb)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (carboplatin, bristol_myers_squibb)
• didanosine (100.0%)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" ] using (didanosine, bristol_myers_squibb)
• OE @973 (100.0%) on 23-jan-2016 [ http://www.jstor.org/stable/4456949 http://www.bms.com/products/Pages/trademark.aspx http://www.bms.com/products/Pages/trademark.aspx  ] using (didanosine, bristol_myers_squibb)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (didanosine, bristol_myers_squibb)
• fosinopril (100.0%)
• OE @809 (94.9%) on 01-feb-2014 [   ] using (fosinopril, bristol_myers_squibb)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (fosinopril, bristol_myers_squibb)
• gatifloxacin (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (gatifloxacin, bristol_myers_squibb)
• OE @823 (94.0%) on 17-mar-2014 [   ] using (gatifloxacin, bristol_myers_squibb)
• hydroxyurea (100.0%)
• OE @803 (100.0%) on 13-jan-2014 [   ] using (hydroxyurea, bristol_myers_squibb)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (hydroxyurea, bristol_myers_squibb)
• irbesartan (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (irbesartan, bristol_myers_squibb)
• metformin (100.0%)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (metformin, bristol_myers_squibb)
• nefazodone (100.0%)
• OE @799 (100.0%) on 25-dec-2013 [ http://www.rxlist.com/serzone-drug/indications-dosage.htm http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4449 http://www.drugbank.ca/drugs/DB01149 http://en.wikipedia.org/wiki/Nefazodone http://bjp.rcpsych.org/content/180/6/528.full http://depression.emedtv.com/nefazodone/nefazodone-p5.html  ] using (nefazodone, bristol_myers_squibb)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (nefazodone, bristol_myers_squibb)
• paraplatin (100.0%)
• OE @1080 (100.0%) on 30-nov-2017 [ https://www.ncbi.nlm.nih.gov/pubmed/15561808 http://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2004.02112.x/abstract https://www.ncbi.nlm.nih.gov/pubmed/16249353 http://www.sagentpharma.com/wpcproduct/carboplatin-injection/  ] using (paraplatin, bristol_myers_squibb)
• SEAL @224 (87.5%) on 24-mar-2011 [ 1 2 3 ] using (paraplatin, bristol_myers_squibb)
• plavix (100.0%)
• SEAL @241 (100.0%) on 22-apr-2011 [ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 ] using (plavix, bristol_myers_squibb)
• CPL @1094 (87.5%) on 01-jan-2018 [ "arg1 is Lipitor and arg2" "arg1 is marketed by arg2" "arg1 is manufactured by arg2" ] using (plavix, bristol_myers_squibb_co)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" "arg1 is marketed by arg2" ] using (plavix, bristol_myers_squibb)
• OE @892 (100.0%) on 26-dec-2014 [ http://www.medicalnewstoday.com/articles/247925.php  ] using (plavix, bristol_myers_squibb)
• tequin (100.0%)
• SEAL @241 (100.0%) on 22-apr-2011 [ 1 ] using (tequin, bristol_myers_squibb)
• OE @809 (85.1%) on 01-feb-2014 [   ] using (tequin, bristol_myers_squibb)
• sprycel (100.0%)
• SEAL @269 (98.4%) on 24-may-2011 [ 1 2 3 4 5 6 ] using (sprycel, bristol_myers_squibb)
• OE @961 (97.0%) on 24-nov-2015 [ http://www.cancer.gov/cancertopics/druginfo/fda-dasatinib http://www.bmspaf.org/ http://news.bms.com/press-release/rd-news/four-year-data-phase-3-dasision-trial-comparing-sprycel-dasatinib-imatinib-fir http://news.bms.com/press-release/rd-news/fda-approves-us-product-labeling-update-sprycel-dasatinib-include-three-year-f http://abcnews.go.com/blogs/extras/2013/12/18/bristol-myers-squibb-responds-to-abc-news/ http://news.bms.com/press-release/rd-news/four-year-data-phase-3-dasision-trial-comparing-sprycel-dasatinib-imatinib-fir http://news.bms.com/press-release/rd-news/fda-approves-us-product-labeling-update-sprycel-dasatinib-include-three-year-f http://www.bmscanada.ca/en/products/sprycel  ] using (sprycel, bristol_myers_squibb)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 was discovered and developed by arg2" ] using (sprycel, bristol_myers_squibb)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" "arg1 is marketed by arg2" ] using (sprycel, bristol_myers_squibb_company)
• serzone (100.0%)
• CPL @1094 (93.8%) on 01-jan-2018 [ "arg2 has voluntarily withdrawn arg1" "arg2 is not recalling arg1" "arg2 voluntarily pulled arg1" "arg2 and marketed under the name arg1" ] using (serzone, bristol_myers_squibb)
• OE @1015 (97.4%) on 09-sep-2016 [ http://www.rxlist.com/serzone-drug/medication-guide.htm http://toxic-torts.lawyers.com/toxic-torts/serzone-lawsuits.html http://www.serzone-antidepressant-drug.com/ http://injury.findlaw.com/product-liability/serzone.html http://www.yourlawyer.com/topics/overview/serzone http://en.wikipedia.org/wiki/Nefazodone http://injury.findlaw.com/product-liability/serzone.html http://www.ahrp.org/infomail/04/05/19.php  ] using (serzone, bristol_myers_squibb)
• SEAL @241 (75.0%) on 22-apr-2011 [ 1 2 ] using (serzone, bristol_myers_squibb)
• taxol (98.4%)
• SEAL @224 (96.9%) on 24-mar-2011 [ 1 2 3 4 5 ] using (taxol, bristol_myers_squibb)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" ] using (taxol, bristol_myers_squibb)
• zerit (98.4%)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg2 under the brand name arg1" "arg2 to lower the price of arg1" ] using (zerit, bristol_myers_squibb)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is marketed by arg2" ] using (zerit, bristol_myers_squibb_company)
• SEAL @263 (93.8%) on 22-may-2011 [ 1 2 3 4 ] using (zerit, bristol_myers_squibb)
• reyataz (96.9%)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" ] using (reyataz, bristol_myers_squibb_company)
• SEAL @221 (96.9%) on 18-mar-2011 [ 1 2 3 4 5 ] using (reyataz, bristol_myers_squibb)
• sustiva (96.9%)
• SEAL @221 (75.0%) on 18-mar-2011 [ 1 2 ] using (sustiva, bristol_myers_squibb)
• CPL @1094 (87.5%) on 01-jan-2018 [ "arg1 marketed by arg2" "arg1 It is manufactured by arg2" "arg1 is manufactured by arg2" ] using (sustiva, bristol_myers_squibb)
• capoten (93.8%)
• CPL @1094 (87.5%) on 01-jan-2018 [ "arg2 under the trade name arg1" "arg2 under the brand names arg1" "arg2 under the brand name arg1" ] using (capoten, bristol_myers_squibb)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" ] using (capoten, bristol_myers_squibb_company)
• videx (93.8%)
• CPL @1095 (50.0%) on 17-jan-2018 [ "arg1 is marketed by arg2" ] using (videx, bristol_myers_squibb_company)
• SEAL @562 (93.8%) on 07-may-2012 [ 1 2 3 4 ] using (videx, bristol_myers_squibb)

NELL has only weak evidence for items listed in grey

• agentworkedondrug
• efavirenz
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is marketed by arg2" ] using (efavirenz, bristol_myers_squibb_company)
• entecavir
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" ] using (entecavir, bristol_myers_squibb)
• ixempra
• SEAL @545 (75.0%) on 02-apr-2012 [ 1 2 ] using (ixempra, bristol_myers_squibb)
• competeswith
• pfizer
• CPL @1115 (50.0%) on 27-aug-2018 [ "arg1 Co and arg2" ] using (bristol_myers_squibb, pfizer)
• CPL @1115 (50.0%) on 27-aug-2018 [ "arg1 Co and arg2" ] using (pfizer, bristol_myers_squibb)